YZi Labs has revealed that they are investing in Renewal Bio, a biotechnology startup that is developing innovative stem cell technology to tackle some of the most significant healthcare issues. This is YZi Lab’s first investment in regenerative medicine since rebranding from Binance Labs earlier this year. This investment will take YZi Lab’s portfolio beyond Web3 and artificial intelligence.
Innovating Regenerative Medicine
Founded in 2022 by Professor Jacob Hanna and Dr. Omri Amirav-Drory, Renewal Bio is on the forefront of a new route to organ transplantation using synthetic embryology. Renewal Bio obtained an exclusive license from the Weizmann Institute of Science for technology that can create stem cell-derived embryoid models capable of producing bona fide, transplantable human cells and tissues.
Renewal Bio’s technology might provide a possible solution to this issue by developing patient-specific cells that would ultimately eliminate the risk of rejection and offer limitless supply of transplantable tissues.
MIT Technology Review stated that Renewal Bio uses induced pluripotent stem cells and moderately controls a simulated process of embryonic development in a laboratory setting. The company’s custom platform leverages advanced biology, hardware, and software to establish procedures for differentiating human iPSCs into mature transplantable cell types.
YZi Labs Broadens Investment Mandate
Overseeing a markedly large portfolio with more than 250 investments busting over $10 billion, YZi Labs executed a major strategic reorganization at the start of 2025 in the dismantling of Binance’s venture arm to structure a new corporate identity focused on three technologies of the future: Web3, AI, and Biotech. This opinion is certainly in step with Changpeng Zhao’s vision for a long-term investment strategy and the deployment of capital into transforming industry sectors beyond the crypto sector.
The Renewal Bio investment reflects YZi Lab’s pledge to this expanded mandate: as one of the firm’s earliest significant biotech allocations, it shows confidence in the convergence of computational technologies and life sciences. The partnership intersects with broader capital venture trends: as funds dedicated to blockchain technology drift into adjacent impact sectors, like blockchain-based software that can bring about a transformation in healthcare data management.
Market Implications and Future Outlook
The international regenerative medicine market is undergoing an explosive expansion, and research suggests there is a considerable opportunity for therapies that can repair, replace, or regenerate tissues and organs in humans. Renewal Bio’s technology may have uses beyond organ transplantation, and offer therapies for infertility, genetic diseases, or diseases of aging.
With decades of experience, Professor Jacob Hanna is both a leading researcher at the Weizmann Institute and the Chief Scientific Advisor for Renewal Bio. His significant research, recently published in Cell and Nature, provides science underpinning the company’s synthetic embryo technology.
YZi Lab’s investment comes at a moment when confidence in crypto and biotech fundraising is increasing, and venture capitalists are ready to reinvest in sectors focused on innovation. This trend follows the well-defined patterns in capital of late stage blockchain venture funding, with our venture capitalists moving away from diversification and real-world utility becoming much more important.
Conclusion
The support of Renewal Bio by YZi Lab represents an important moment in the advancement of Web3 venture capital. By supporting technology that is a breakthrough in regenerative medicine, YZi demonstrates that blockchain-adjacent technology investors can be a lever to advance innovation well beyond the digital nature of that investment. As Renewal Bio progresses toward clinical applications, it offers unique proof of concept for decentralized science. Its success would show precisely how wealth generated in the cryptocurrency space can spur advances in tackling humanity’s biggest healthcare challenges. There currently exists a global crisis in organ supply, and we need high-impact innovative solutions. The intersection of advanced biotechnology and strategic capital serves as one of the only pathways ahead worth pursuing.
